Galmed pharmaceuticals provides additional positive data from the open label part of armor study and reports third quarter 2021 financial results

Tel aviv, israel, nov. 8, 2021 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted scd1 modulator aramchol™, an oral therapy for the treatment of nonalcoholic steatohepatitis, or nash and fibrosis, provides today updated information on the company's scientific and clinical development programs and reports financial results for the three and nine months ended september 30, 2021.
GLMD Ratings Summary
GLMD Quant Ranking